What is Chronic Obstructive Pulmonary Disorder Market Scope?
Chronic obstructive pulmonary disease is basically a chronic inflammatory lung disease that hereby causes obstructed airflow from the lungs. Symptoms include difficulty breathing, coughing, mucus (sputum) build-up, and wheezing. It is usually caused by long-term exposure to irritating gases or particles, most often from cigarette smoke. People with COPD are at increased risk of developing heart disease, lung cancer, and a variety of other conditions. Emphysema and chronic bronchitis are the two most common conditions that contribute to COPD. These two conditions usually occur together and can vary in severity in people with COPD. Chronic bronchitis is inflammation of the lining of the bronchi that carry air to and from the air sacs (alveoli) of the lungs. It is characterized by the daily production of cough and mucus (sputum). Emphysema is a condition in which the alveoli at the end of the smallest airways (bronchioles) in the lungs are destroyed from harmful exposure to cigarette smoke and other irritating gases and particles. Although COPD is a progressive disease that gets worse over time, COPD is treatable. With proper treatment, most people with COPD can achieve good symptom control and quality of life, and a lower risk of other related conditions. In 2016, COPD was the third leading cause of death worldwide, with around 3 million deaths that year. In the United States, the state of West Virginia had the highest COPD prevalence in 2017, with nearly 14 percent of adults in the state being diagnosed with the disease. By comparison, only 3.4 percent of Hawaiian adults were diagnosed with COPD. The lowest rate in the US is higher among certain populations. 11 percent of Native American / Alaskan people have been diagnosed, compared with just 3 percent of Hispanics.
The Chronic Obstructive Pulmonary Disorder market study is being classified by Type (Chronic Bronchitis and Emphysema), by Application (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) and major geographies with country level break-up.
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that Players from European will contribute to the maximum growth of Global Chronic Obstructive Pulmonary Disorder market throughout the predicted period.
AstraZeneca (United Kingdom), Boehringer Ingelheim (Germany), GlaxoSmithKline plc (United Kingdom), Novartis AG (Switzerland), Teva Pharmaceuticals (Israel), Ache Laboratorios Farmaceuticos (Brazil), Sunovion Pharmaceuticals Inc. (United States), CHIESI Farmaceutici S.p.A. (Italy), Almirall (Spain), Aquinox Pharmaceuticals (United States), Orion Corporation (Finland), Mylan N.V. (United States) and Ario Pharma (United Kingdom) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Odan Laboratories (Canada), Astellas Pharma (Japan) and BioMarck Pharmaceuticals (United States).
Analyst at AMA have segmented the market study of Global Chronic Obstructive Pulmonary Disorder market by Type, Application and Region.
On the basis of geography, the market of Chronic Obstructive Pulmonary Disorder has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Market Influencers and their development strategies
In January 2019, CHIESI Farmaceutici S.p.A. an exclusive global license agreement with TiumBio, a private clinical-stage biotech company based in South Korea. TiumBio specializes in researching innovative drugs for rare diseases. This agreement aims to develop innovative molecules for the treatment of respiratory diseases.
In June 2019, AstraZeneca, an Anglo-Swedish multinational pharmaceutical company, announced the approval of Breztri Aerosphere, a pressurized metered-dose inhaler with integrated triple combination therapy for patients with moderate to severe COPD in Japan.
Various regulators like the European Commission, the FDA, the Ministry of Health, Labor, and Social Affairs (MHLW), and a cabinet-level ministry of the Japanese government, had thereby approved the usage of combination drugs for treating COPD. In April 2019, the FDA approved combination therapy for the maintenance of COPD. A combination of a long-acting muscarinic antagonist (LAMA), aclidinium bromide (400 µg) and a long-acting beta-agonist (LABA), formoterol fumarate (12 µg), has been approved by the FDA for the maintenance and treatment of chronic obstructive pulmonary disease.
Influencing Market Trend
- Advanced Healthcare Infrastructure
- Demand For Home Care Therapeutics Devices
- Rising Awareness among Population about the Use of Generic Drug
- An Increase in Incidence and Prevalence of Asthma and COPD
- Increasing Consumption of Tobacco among Youth Population
- High Disposable Income, And Lifestyle Changes
- Increasing Automotive and Industrial Exhaust Gases
- Increasing R&D Investment by Government and Major Players
- The Rise in the Number of Initiatives Undertaken By Government and Non-Government Organizations
- High Cost of the COPD Treatment
- The Dearth of Awareness and Knowledge among Population about COPD Symptoms and Indications
- Increasing Problem Associated With Patent Expiry
Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Providers of Chronic Obstructive Pulmonary Disorder Treatment, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry
Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research & Media features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.